Drug-Induced Taste and Smell Alterations
Drug-Induced Taste and Smell Alterations
复制标题
药物引起的味觉和嗅觉改变
DOI：
10.2165/11593120-000000000-00000
复制
发表时间：
2011
期刊：
影响因子：
4.2
通讯作者：
C. Blandizzi
中科院分区：
文献类型：
--
作者：
M. Tuccori;F. Lapi;A. Testi;E. Ruggiero;U. Moretti;A. Vannacci;R. Bonaiuti;L. Antonioli;M. Fornai;G. Giustarini;C. Scollo;T. Corona;F. Ferrazin;L. Sottosanti;C. Blandizzi
摘要背景：药物相关味觉和/或嗅觉障碍的频率和临床特征目前尚不清楚。
目的：本研究的目的是确定意大利自发性药物不良反应（ADR）报告数据库中报告的与味觉和嗅觉改变相关的主要药物类别。
方法：采用病例/非病例研究方法，调查药物与味觉或嗅觉改变之间的关系。使用报告比值比（ROR）作为风险性的衡量标准。病例定义为至少发生1起与味觉或嗅觉障碍相关ADR的患者。非病例包括所有没有任何与味觉或嗅觉改变相关的ADR的患者。
结果：根据入选标准，共纳入52166篇文献。总体而言，确定了182例药物相关味觉和/或嗅觉功能障碍病例。报告了大环内酯类的统计学显著性未校正ROR（n = 31; 7.1; 95% CI 4.8，10.5），特比萘芬（属于解剖治疗化学分类D01AE的抗真菌药组中报告的唯一药物）[n = 17; 76.4; 95% CI 44.0，132.6]，氟喹诺酮类（n = 15; 1.7; 95%CI 1.0，2.8）和蛋白激酶抑制剂（n = 10; 4.0; 95%CI 2.1，7.7）。当按性别和年龄类别调整ROR时，所有上述药物类别的比例失调仍具有统计学显著性。
结论：味觉和/或嗅觉异常是常见的，有时是非预期的，并且通常是药物治疗期间患者的持续主诉。医生应了解这些ADR对患者生活质量的影响。
AbstractBackground: The frequency and clinical features of drug-related taste and/or smell impairments are currently unclear.
Objective: The aim of this study was to identify major drug classes associated with taste and smell alterations reported to the Italian spontaneous adverse drug reaction (ADR) reporting database.
Methods: The association between drug and altered taste or smell was investigated by case/non-case methodology. The reporting odds ratio (ROR) was used as a measure of disproportionality. Cases were defined as patients with at least one ADR related to taste or smell impairments. The non-cases included all patients without any ADRs related to taste or smell alterations.
Results: According to the selection criteria, 52 166 reports were included in the analysis. Overall, 182 cases of drug-related taste and/or smell dysfunctions were identified. Statistically significant unadjusted RORs were reported for macrolides (n = 31; 7.1; 95% CI 4.8, 10.5), terbinafine (the only drug reported within the group of antimycotics belonging to the Anatomical Therapeutic Chemical class D01AE) [n=17; 76.4; 95% CI 44.0, 132.6], fluoroquinolones (n= 15; 1.7; 95% CI 1.0, 2.8) and protein kinase inhibitors (n= 10; 4.0; 95% CI 2.1, 7.7). When RORs were adjusted for sex and age category, the disproportion remained statistically significant for all of the previously mentioned drug classes.
Conclusions: Taste and/or smell abnormalities are common, sometimes unexpected and often persistent complaints of patients during pharmacological treatments. Physicians should be aware of the impact of these ADRs on patients’ quality of life.
影响因子：
5
作者：
MICKEY, RM;GREENLAND, S
通讯作者：
GREENLAND, S